All In Biotech

Drug Trial Radar · NCT00529373

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Last checked: Nov 19, 2026Latest source record: Jun 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 16,071 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

16,071

Actual

Start

Sep 13, 2007

Primary completion

Nov 14, 2012

Study completion Feb 1, 2017

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Sep 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis. In a placebo-controlled extension of the base study, participants continued to receive the same blinded study medication for a total of up to 5 years of blinded study medication combined between the base study and the extension. After participants received 5 years of blinded study medication, they received open-label odanacatib through the end of the first extension. Participants were then invited to enroll in a second extension study in which they received open-label odanacatib for an additional 5 years. Two imaging substudies (PN032-Base/Extension and PN035) were conducted for participants in the MK-0822-018 Study. Additional safety information was collected for participants who discontinued from the base study or the blinded first extension in an observational follow-up study, MK-0822-083 (EudraCT number: 2007-002693-66) .

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • OdanacatibDrug

    50 mg tablet orally once weekly (OW)

  • Placebo for OdanacatibDrug

    50 mg tablet orally OW

  • Vitamin D3Dietary supplement

    5600 IU orally OW

  • Calcium carbonateDietary supplement

    If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Base Study: Time From Baseline to First Morphometrically-Assessed Vertebral FractureTime frame: Up to approximately 60 months of observation
  2. Base Study: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)Time frame: Up to approximately 60 months of observation
  3. Base Study: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)Time frame: Up to approximately 60 months of observation
  4. Base Study + First Extension: Time From Baseline to First Morphometrically-Assessed Vertebral FractureTime frame: Up to approximately 74 months of observation
  5. Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Hip Fracture (Adjudicated)Time frame: Up to approximately 74 months of observation
  6. Base Study + First Extension: Time From Baseline to First Osteoporotic Clinical Non-Vertebral Fracture (Adjudicated)Time frame: Up to approximately 74 months of observation
  7. Base Study + First Extension: Rate of Adverse EventsTime frame: Up to approximately 74 months of observation
  8. Base Study + First Extension: Rate of Discontinuations From Study Treatment Due to an Adverse EventTime frame: Up to approximately 74 months of observation
  9. Base Study + First Extension + Second Extension: Percent Change From Baseline in Bone Mineral Density (BMD) Measurements of the Total HipTime frame: Baseline and once yearly, up to approximately 108 months of observation
  10. Second Extension: Number of Participants Who Experienced an Adverse EventTime frame: Up to approximately 34 months of observation
  11. Second Extension: Number of Participants Discontinuing Study Treatment Due to an Adverse EventTime frame: Up to approximately 34 months of observation
  12. Imaging Substudy PN032-Base: Percent Change From Baseline in Volumetric Bone Mineral Density (vBMD) at the Lumbar Spine Using Quantitative Computed TomographyTime frame: Baseline, Month 24
  13. Imaging Substudy PN032-Base + Extension: Percent Change From Baseline in vBMD at the Lumbar Spine Using Quantitative Computed TomographyTime frame: Baseline, Month 60
  14. Sarcopenia Substudy PN035: Change From Baseline in Appendicular Lean Body Mass (aLBM)Time frame: Baseline and once yearly up to 4 years
  15. Sarcopenia Substudy PN035: Change From Baseline in Short Physical Performance Battery (SPPB) ScoreTime frame: Baseline and once yearly up to 4 years
  16. Sarcopenia Substudy PN035: Change From Baseline in Gait SpeedTime frame: Baseline and once yearly up to 4 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.